Introduction {#s1}
============

The *Escherichia coli* GroE chaperonin system, which comprises GroEL and its co-factor GroES, assists protein folding in vivo and in vitro in an ATP-dependent manner ([@bib23]; [@bib16]; [@bib9]; [@bib7]). Binding of GroES to GroEL forms a cage in which encapsulated substrate proteins can fold in isolation from bulk solution. The GroE system has been studied intensively for more than three decades, but it is still unclear and controversial whether its cavity is a 'passive cage' in which protein substrate aggregation is prevented but the folding pathway is unchanged or a chamber in which the folding process is altered in some manner. It is also unclear whether encapsulation in the GroE cavity is thermodynamically stabilizing, for example because of confinement, or destabilizing owing, for example, to a diminished hydrophobic effect.

The effects of encapsulation on folding kinetics have been examined in different studies but it has been difficult to generalize its impact, in part, because it may depend on the properties of the protein substrate studied such as its size and charge. According to some studies, encapsulation prevents aggregation but does not alter the protein substrate's folding pathway and kinetics ([@bib11]; [@bib25]). In the case of rhodanese, for example, it was reported that encapsulation retards the folding of its C-terminal domain but has no effect on its N-terminal domain ([@bib10]). By contrast, other studies have suggested more 'active' models according to which folding is accelerated in the GroEL cavity compared to bulk solution. Recent work showed, for example, that GroEL repairs a folding defect of a mutant of maltose-binding protein by accelerating the formation of an on-pathway intermediate ([@bib32]). Accelerated folding upon encapsulation has been attributed to steric confinement and the negative charges of the cavity walls ([@bib21]). It has also been attributed to substrate interactions with the cavity-protruding C-terminal tails of GroEL, which comprise Gly-Gly-Met repeats ([@bib21]; [@bib29]; [@bib28]). In addition, GroEL-mediated folding can be affected by the cavity-confined water, which can enhance the hydrophobic effect (and thus accelerate folding) by accumulating near the cavity walls ([@bib4]) or diminish it (and thus slow folding) by being more ordered. Finally, an even more 'active' mechanism has been proposed according to which encapsulated misfolded protein substrates undergo ATP-promoted forced-unfolding ([@bib29]), in accordance with the iterative annealing model ([@bib24]), thereby giving them further opportunity to fold correctly. The iterative annealing model predicts higher folding yields but it has been suggested that annealing can also lead to accelerated folding ([@bib21]; [@bib8]; [@bib29]; [@bib28]).

In contrast with the many and often conflicting studies on the kinetic effects of encapsulation, there have been virtually no reports on the thermodynamic effects of encapsulation. One complication in understanding the thermodynamic effects of encapsulation has been that protein substrates spend variable amounts of time folding in the cavity and in bulk solution because of GroEL-GroES cycling and the leakiness of its cavity ([@bib14]). As shown below, such leakiness is even greater in the complex of single-ring GroEL with GroES, which was used in some studies ([@bib10]) and has been suggested to form during GroEL's normal reaction cycle ([@bib31]). Another complication has been that measuring protein stability usually involves perturbations such as temperature or solution changes, which could also affect the stability of the chaperonin itself. The goal of the work described here was, therefore, to establish a system that would allow measuring the stability of an encapsulated protein in a non-leaky and unperturbed GroE complex. An appropriate system was found to be a chimera of dihydrofolate reductase from *Moritella profunda* (DHFR~Mp~) fused to eGFP, which is encapsulated in the football-shaped and non-cycling BeF~x~-stabilized GroEL-GroES~2~ complex ([Figure 1](#fig1){ref-type="fig"}). Consequently, we were able to isolate the thermodynamic effect of encapsulation from other effects associated with GroEL-GroES cycling. Our results show that protein stability in the GroEL cavity is reduced dramatically in comparison with bulk solution.

![Scheme showing the experimental system used to measure protein stability in the chaperonin cage.\
A chimera was formed by fusing dihydrofolate reductase from *Moritella profunda* (DHFR~Mp~, PDB ID: 3IA4) to the C-terminus of eGFP (PDB ID: 2Y0G) via a linker. This chimera was then encapsulated in the cavity of the BeF~x~-stabilized football--shaped GroEL-GroES~2~ complex, which is depicted schematically with GroEL in purple and GroES in green. The cavity volume is about 175,000 Å^3^ whereas that of the chimera (which is not drawn to scale) is about 58,000 Å^3^ assuming 1.23 Å^3^ per Da.](elife-56511-fig1){#fig1}

Results {#s2}
=======

Design and construction of a model protein substrate {#s2-1}
----------------------------------------------------

We chose to use dihydrofolate reductase from *Moritella profunda*, a psychrophilic bacterium with an optimal growth temperature at 2°C, as a model substrate since it is a relatively unstable protein at room temperature [@bib30] whose folding can be monitored easily by measuring the regain in enzyme activity. DHFR~Mp~ was fused to the C-terminus of enhanced green fluorescent protein (eGFP) in order to further destabilize it as observed before for other proteins ([@bib17]; [@bib3]). The fusion to eGFP also facilitated easy and sensitive determination of the location of the substrate, that is whether it is in the cavity or has leaked outside of it. Under our conditions, the apparent melting temperature, T~m~, in bulk solution of DHFR~Mp~ alone was found to be about 41.2 (±1.8) °C whereas DHFR~Mp~ fused to eGFP was found to be strongly destabilized with a T~m~ of 22.8 (±1.1) °C ([Figure 2](#fig2){ref-type="fig"}). eGFP in the chimera was also found to be destabilized in bulk solution relative to eGFP alone, but to a lesser extent, with T~m~ values of 76.3 (±0.3) and 81.3 (±1.3) °C, respectively.

![Melting temperature analysis of eGFP, DHFR~Mp~ and their chimera.\
(**A**) DHFR~Mp~, eGFP and a chimera of these proteins were subjected to temperature denaturation in bulk solution using a Real-Time PCR machine. Denaturation was monitored by measuring the change in fluorescence of the SYPRO Orange reagent. Each trace represents the average of at least six experiments. (**B**) Plots of the first derivatives of the denaturation curves as a function of temperature. Melting points were determined from these plots by using the StepOne Software v2.3.\
Figure 2---source data 1.Temperature melts of eGFP, DHFR~Mp~and their chimera.](elife-56511-fig2){#fig2}

Identifying conditions for minimizing escape of encapsulated substrates {#s2-2}
-----------------------------------------------------------------------

GroEL and GroES can form either GroEL-GroES bullet-shaped or GroEL-GroES~2~ football-shaped complexes. It has been reported that the GroEL-GroES~2~ complex is stabilized in the presence of BeF~x~ ([@bib20]). We, therefore, tested whether eGFP remains encapsulated in the BeF~x~-stabilized 'football' complex over a sufficiently long period of time. BeF~x~-stabilized and eGFP-containing 'football' complexes were prepared, purified by gel-filtration and then allowed to stand overnight at room temperature. The samples were then analyzed by gel-filtration in order to determine the extent, if any, of substrate escape. The results show that all the eGFP co-eluted with GroEL and GroES, thereby indicating that the complex remained intact and no escape occurred ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Two other proteins, the p53 core domain and a chimera of the engrailed homeodomain transcription factor with eGFP with respective masses of 22.4 and 42.9 kDa, were also tested in this manner and found to not escape (data not shown). Previously, it was believed that substrates encapsulated in the cage formed by single-ring GroEL in complex with GroES cannot escape since dissociation of GroES from one ring of GroEL is triggered by ATP binding to the opposite ring ([@bib15]). Experiments carried out with eGFP encapsulated in the cavity of single-ring GroEL in complex with GroES showed, however, that massive substrate leakage took place ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

Folding of the DHFR~Mp~ part of the chimera in the GroEL cavity {#s2-3}
---------------------------------------------------------------

BeF~x~-stabilized 'football' complexes containing the chimera were purified and the DHFR activity of the encapsulated chimera was monitored at 23°C (i.e. near the apparent T~m~ of the fused DHFR~Mp~ in bulk solution) by following the change in absorbance at 340 nm, upon addition of the substrates NADPH and dihydrofolate (DHF). The data show a lag phase followed by a linear phase ([Figure 3](#fig3){ref-type="fig"}) before activity starts to diminish owing to substrate depletion. Strikingly, the lag phase is absent when the chimera is free in bulk solution ([Figure 3](#fig3){ref-type="fig"}). One possible reason for the presence of the lag phase, in the case of the encapsulated chimera, is that the added substrates (DHF and NADPH) need to diffuse into the cavity. In such a case, the rate constant associated with the lag phase should increase with increasing substrate concentrations. Alternatively, the lag phase may reflect substrate (DHF and/or NADPH)-promoted folding of the DHFR~Mp~ part of the chimera, which is destabilized in the cavity relative to bulk solution. Substrate (DHF and/or NADPH)-promoted folding of the DHFR~Mp~ part of the chimera can take place via a mechanism of conformational selection, that is the substrates bind only to the folded state, thereby shifting the equilibrium in its favor. In such a case, the rate constant associated with the lag phase should decrease with increasing substrate concentrations ([@bib27]). Alternatively, substrate-promoted folding of the DHFR~Mp~ part of the chimera can also occur via a mechanism of induced fit in which case the rate constant associated with the lag phase should increase with increasing substrate concentrations. In other words, an increase in the rate constant of the lag phase with increasing substrate concentration can be due to substrate penetration or induced fit, whereas a decrease is evidence for conformational selection. Discriminating between these mechanisms can, therefore, be achieved by measuring the substrate concentration dependence of the rate constant of the lag phase.

![DHFR~Mp~ activity of the GroE-encapsulated chimera shows an initial lag phase.\
(**A**) Representative traces are shown for the DHFR~Mp~ activities of free (29 nM) and GroE-encapsulated (40 nM) chimera upon addition of 250 μM dihydrofolic acid and 300 μM NADPH. The reactions were monitored by measuring the decrease in absorbance at 340 nm as a function of time. An initial lag phase is observed in the case of the encapsulated chimera but not the free one. (**B**) The lag and linear phases in the data for the encapsulated chimera were fitted to [Equation 1](#equ1){ref-type="disp-formula"}. (**C**) Good fits were obtained as indicated by plots of the residuals with random deviations about zero. See Materials and methods for additional details.\
Figure 3---source data 1.Representative reaction progress curves of free and caged chimera in the presence of 250 μM DHF.](elife-56511-fig3){#fig3}

The change in the absorbance at 340 nm due to the enzyme activity of the encapsulated or free chimera was, therefore, monitored in the presence of different concentrations of DHF and a fixed concentration of NADPH. The data were fitted to:$$\left\lbrack P \right\rbrack = Vt + A\left( {e^{- \lambda t} - 1} \right)$$where \[P\] is the product concentration (or the absorbance at 340 nm which is proportional to it), *V* is the slope that corresponds to the linear steady-state velocity of the reaction and A and *λ* are the respective amplitude and rate constant of the lag phase. [Equation 1](#equ1){ref-type="disp-formula"} can be derived for the reaction scheme $\left. E_{U}\rightleftarrows E_{F}\rightleftarrows ES \right.$, where E~U~, E~F~ and ES designate the respective unfolded, folded and substrate-bound folded states of the protein (E), assuming that ligand binding is fast relative to the folding and unfolding steps. In such a case, the rate constant, *λ*, is given by [@bib27]:$$\lambda = k_{1} + \frac{k_{- 1}k_{- 2}}{k_{2}\left\lbrack S \right\rbrack + k_{- 2}} = k_{1} + \frac{k_{- 1}}{K_{a}\left\lbrack S \right\rbrack + 1}$$where *k*~1~ and *k*~-1~ are the respective folding and unfolding rate constants, *k*~2~ and *k*~-2~ are the respective substrate association and dissociation rate constants and *K*~a~ = *k*~2~/*k*~-2~ is the substrate association constant. Inspection of [Equation 2](#equ2){ref-type="disp-formula"} shows that the value of the observed rate constant, *λ*, decreases with increasing substrate concentration as observed here in the case of the encapsulated chimera ([Figure 4A](#fig4){ref-type="fig"}). This finding indicates that the DHFR~Mp~ part of the chimera is significantly destabilized in the cavity, but not in bulk solution (where the lag phase is absent), and that the substrates DHF and NADPH shift its equilibrium toward the folded state via a conformational selection mechanism. In agreement with this finding, temperature melts of the chimera in bulk solution show that both DHF and NADPH stabilize its DHFR~Mp~ part ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). It should be noted that, in principle, a similar kinetic behavior would be observed for a scheme $\left. E'\rightleftarrows E_{F}\rightleftarrows ES \right.$, that is when the equilibrium is between the folded protein and a mis-folded inactive species, E' (instead of between the folded and unfolded species). This possibility is unlikely, however, because it was found that only 20% of human DHFR mis-folds inside the cavity of the non-cycling complex of single-ring GroEL with GroES ([@bib11]). In such a case, the expected lag phase due to the mis-folded population would not be observed owing to the activity of the remaining DHFR, which does not mis-fold. Moreover, according to this model, the mis-folded state is much more stable than the folded state, which is in violation of Anfinsen's dogma that the native state is at the minimum free energy if the conditions in the cavity are assumed to favor folding.

![Encapsulation in the GroE cavity affects folding and enzyme activity of the DHFR~Mp~ part of the chimera.\
(**A**) Plot of the observed folding rate constant, λ, of the DHFR~Mp~ part of the chimera inside the cavity as a function of the DHF concentration. The data were fitted to [Equation 2](#equ2){ref-type="disp-formula"}, thereby yielding estimates of the folding and unfolding rate constants. These experiments were carried out in duplicate. (**B**) Reduced χ^2^ surfaces for the folding and unfolding rate constants *k*~1~ and *k*~-1~, respectively. The relatively steep chi-squared surfaces suggest that the extracted parameters are well defined with relatively narrow confidence intervals. (**C**) Plot of the initial enzyme velocity of the DHFR~Mp~ part of the chimera inside the cavity and in bulk solution, as a function of the DHF concentration. The data were fitted to the Michaelis-Menten equation. In the case of the encapsulated chimera, the initial enzyme velocities were obtained by fitting the data of decrease in absorption at 340 nm as a function of time to [Equation 1](#equ1){ref-type="disp-formula"}. Error bars in both panels represent standard errors.\
Figure 4---source data 1.Reaction progress curves of caged chimera in the presence of different concentrations of DHF.\
Figure 4---source data 2.Reaction progress curves of free chimera in the presence of different concentrations of DHF.](elife-56511-fig4){#fig4}

Values of the folding and unfolding rate constants were obtained by fitting the plot of *λ* as a function of substrate (DHF) concentration to [Equation 2](#equ2){ref-type="disp-formula"} and found to be 1.4 (±0.4) x 10^−4^ and 7.3 (±0.8) x 10^−3^ sec, respectively ([Figure 4A,B](#fig4){ref-type="fig"}). Consequently, the stability of the cavity-confined fused DHFR~Mp~, in the absence of the substrates DHF and NADPH, is 2.4 (±0.2) kcal mol^−1^, that is the folded state is extremely destabilized so that it is less stable than the unfolded state. By contrast, the stability in bulk solution of fused DHFR~Mp~, in the absence of the substrates DHF and NADPH, is −3.45 (±0.09) kcal mol^−1^ ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). This value was determined by measuring the stability of fused DHFR~Mp~, in the presence of different concentrations of NADPH, in order to minimize aggregation that takes place in bulk solution, and then extrapolating to zero concentration of NADPH. Taken together, the results obtained here show that encapsulation in the GroEL cavity destabilizes the DHFR~Mp~ part of the chimera by more than five kcal mol^−1^ relative to bulk solution. Interestingly, analysis of the linear phase in the progress curves (e.g. in [Figure 3](#fig3){ref-type="fig"}) shows that the steady-state enzyme activity of DHFR~Mp~ is also affected by encapsulation. The K~m~ value of the encapsulated fused DHFR~Mp~ for DHF is about 0.28 (±0.09) mM and, thus, about 10-fold higher than the value of 33 (±2) µM measured in bulk solution ([Figure 4C](#fig4){ref-type="fig"}), in agreement with a previous determination ([@bib30]). The value of k~cat~ may also be affected but these values are difficult to determine because of uncertainties regarding the active protein concentrations.

In order to test whether the destabilization of the cavity-confined fused DHFR~Mp~ is due to its interaction with the cavity walls, we carried out fluorescence anisotropy decay measurements. Fits of the decay curves for the free and caged chimeras yielded similar rotational times of 22.85 (±0.30) ns and 25.40 (±0.45) ns, respectively ([Figure 5](#fig5){ref-type="fig"}). Likewise, the fits of the decay curves for free and caged eGFPs yielded similar rotational times of 14.38 (±0.20) ns and 15.90 (±0.25) ns, respectively ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), in agreement with previous work ([@bib18]). The results indicate free mobility of the chimera and eGFP inside the GroEL football complex. It is, therefore, unlikely that the cavity-induced thermodynamic destabilization of the fused DHFR~Mp~ is due to interactions with the cavity walls.

![Time-resolved fluorescence anisotropy measurements of free and GroEL-caged chimera.\
(**A**) Fluorescence anisotropy decay curves of free (green) and caged (red) chimeras were measured as described in the Materials and methods. Fits of the decay curves for free and caged chimera to a single exponential (green and red solid lines, respectively) yielded rotational times of 22.85 (±0.30) ns and 25.40 (±0.45) ns, respectively. The results indicate no restriction on the mobility of the chimera inside the GroEL football complex. Each experiment was carried out in duplicate. (**B**) Plots of the residuals for the fits in panel A.\
Figure 5---source data 1.Time-resolved fluorescence anisotropy measurements of free and caged eGFP.](elife-56511-fig5){#fig5}

Discussion {#s3}
==========

Our results show that protein stability in the chaperonin cage is reduced dramatically by more than 5 kcal mol^−1^ compared to that in bulk solution. Given that steric confinement alone is expected to be stabilizing, our results indicate that protein destabilization in the cavity is likely to be due to hydrophobic and/or electrostatic effects. One possibility is that water in the cavity becomes more ordered in the presence of a substrate protein, thereby leading to a diminished hydrophobic effect. All-atom molecular dynamics simulations have shown that pairwise hydrophobic interactions are destabilized in hydrophobic nanopores when they contain water at bulk density ([@bib26]), as indicated by some evidence in the case of the GroEL cavity ([@bib6]). The cavity walls of the 'football' complexes in our experiments are, however, charged and the extent of destabilization would, therefore, depend on many factors including the distribution of charges on the cavity walls, the cavity geometry and the presence of regions where the water structure is disrupted. Future simulations should test how these various factors affect pairwise interactions under confinement.

Similar to man-made machines, biological machines such as GroEL cycle between states that differ in their structural and functional properties. Substrate proteins first bind to GroEL in its apo state and can become destabilized through binding to its hydrophobic cavity walls (see, for example, [@bib12]). ATP binding to the GroEL-protein substrate complex, which follows, can cause further unfolding due to a stretching force applied to the substrate protein upon ATP-binding-promoted conformational changes ([@bib28]). Next, protein substrates are encapsulated in the GroES-capped cavity for 1--10 s ([@bib2]) before being discharged into bulk solution. Here, we have succeeded in isolating the effect of this key step on substrate stability and found that it can also lead to protein destabilization. It is important to point out, however, that the magnitude (and possibly direction) of the effect is likely to depend on the protein substrate's size and other properties. Hence, future studies should employ the strategy developed here to examine other proteins.

Finally, it is important to note that our finding that the cavity environment is destabilizing supports the iterative annealing mechanism of action proposed for the chaperonin GroEL ([@bib24]; [@bib22]). According to this mechanism, protein substrates undergo kinetic partitioning, during each reaction cycle of GroEL, between productive folding to the native state and mis-folding. The remaining fraction of mis-folded protein substrates are then rebound to GroEL and (partially) unfolded, thereby giving them new opportunity to fold correctly. Our results show that (partial) unfolding is achieved not only because of binding to the hydrophobic cavity of the apo state and ATP-promoted forced unfolding, as shown before by others, but also because it is strongly favored thermodynamically under the conditions in the GroES-capped cavity.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                Designation                              Source or reference                                             Identifiers         Additional information
  (species) or resource                                                                                                                                     
  ---------------------------- ---------------------------------------- --------------------------------------------------------------- ------------------- ---------------------------------------------------------
  Recombinant DNA reagent      Pet21d plasmid for expressing DHFR~Mp~   Gift from Prof.\                                                                    
                                                                        S. Fleishman                                                                        

  Recombinant DNA reagent      Pet21a plasmid for expressing eGFP       PMID:[29066625](https://www.ncbi.nlm.nih.gov/pubmed/29066625)                       

  Strain, strain background\   *E. coli* Rosetta cells                  Novagen                                                                             
  (*Escherichia coli*)                                                                                                                                      

  Strain, strain background\   *E. coli* BL21 cells                     PMID:[3537305](https://www.ncbi.nlm.nih.gov/pubmed/3537305)                         
  (*Escherichia coli*)                                                                                                                                      

  Sequence-based reagent       TEV site insertion\                      This work                                                       PCR primer          5'-ACTCGAGCACCACCACCACCACCACTGA-3'
                               -forward                                                                                                                     

  Sequence-based reagent       TEV site insertion\                      This work                                                       PCR primer          5'-GCTGTATAAGGGCAACCTGTATTTTCAGGGCACTCGAGCACCACC-3'
                               -reverse                                                                                                                     

  Sequence-based reagent       DHFR~Mp~ cloning\                        This work                                                       RF cloning primer   5'-CCTGTATTTTCAGGGCATGATCGTAAGCATGATTGCCGCACTGGCG-3'
                               -forward                                                                                                                     

  Sequence-based reagent       DHFR~Mp~ cloning\                        This work                                                       RF cloning primer   5'-GGTGGTGGTGGTGCTCGAGTTCACTCGAGTTTGACTCTTTCAAGTAGAC-3'
                               -reverse                                                                                                                     

  Chemical compound, drug      SYPRO Orange protein gel stain           Sigma                                                           Cat\#S5692          Used at a dilution of 1:5000

  Software, algorithm          MATLAB 2015b                             MathWorks                                                                           

  Other                        HisTrap 5 ml columns                     GE\                                                             Cat\#17-5248-02     
                                                                        Healthcare                                                                          

  Other                        PD 10 desalting columns                  GE\                                                             Cat\#17-0851-01     
                                                                        Healthcare                                                                          

  Other                        Superdex 75 10/300 column                GE\                                                             Cat\#29-1487-21     
                                                                        Healthcare                                                                          

  Other                        Superose 6 10/300 column                 GE\                                                             Cat\#17-5172-01     
                                                                        Healthcare                                                                          

  Other                        Q Sepharose column                       GE\                                                             Cat\#17-1014-01     
                                                                        Healthcare                                                                          
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Construction of the chimera of DHFR~Mp~ with eGFP {#s4-1}
-------------------------------------------------

The Pet21a plasmid containing the gene for eGFP (with the mutation A206K that stabilizes its monomeric state) and an N-terminal His~7~-tag ([@bib1]) was amplified by PCR using the following respective forward and reverse primers:

5'-ACTCGAGCACCACCACCACCACCACTGA-3'

5'-GCTGTATAAGGGCAACCTGTATTTTCAGGGCACTCGAGCACCACC-3'. This amplification resulted in introducing a TEV protease cleavage site at the C-terminus of eGFP. The gene coding for DHFR~Mp~ was then introduced at the 3' end of the TEV coding sequence by restriction-free cloning using the forward and reverse primers:

5'-CCTGTATTTTCAGGGCATGATCGTAAGCATGATTGCCGCACTGGCG-3'

5'-GGTGGTGGTGGTGCTCGAGTTCACTCGAGTTTGACTCTTTCAAGTAGAC-3', respectively. The final gene product codes for eGFP with an N-terminal His~7~-tag fused at its C-terminus to DHFR~Mp~ via a linker sequence containing a TEV protease cleavage site.

Expression and purification of the chimera of DHFR~Mp~ with eGFP {#s4-2}
----------------------------------------------------------------

*E. coli* BL21 cells ([@bib19]) harboring the Pet21d plasmid containing the gene for the chimera were inoculated into 250 ml 2 x TY with 100 µg/ml ampicillin and grown at 37°C until an O.D. of 0.6 was reached. Expression was induced by addition of 0.5 mM IPTG and growth was continued overnight at 16°C. The cells were then spun at 11,970 g for 20 min at 4°C, resuspended in 10% sucrose solution, spun again at 3,452 g for 30 min at 4°C and the pellet was stored at −80°C until purification. The pellet was resuspended in 30 ml of 50 mM Tris-HCl buffer (pH 7.5) containing 10 mM NaCl and 1 mM DTT (buffer A) with 8 M urea to prevent proteolysis. The cells were lysed using a French press (three passes) and sonication (4 cycles of 20 s sonication at 70% intensity and 60 s intervals). The lysate was then centrifuged at room temperature for 10 min at 24,610 g and again at 38,720 g for 30 min. The supernatant was diluted with buffer A to 6 M urea and loaded on a 140 ml Q-Sepharose column pre-equilibrated with buffer A containing 6 M urea. The column was then washed with 200 ml buffer A containing 6 M urea and with 150 ml of this buffer containing also 150 mM NaCl. A 5 ml HisTrap column, which was pre-equilibrated with buffer A containing 6 M urea, was connected downstream to the Q-Sepharose column and both columns were washed with 200 ml of buffer A with 1 M NaCl. The Q-Sepharose column was then removed and the HisTrap column was washed at room temperature with 75 ml of 50 mM Tris-HCl buffer (pH 7.5) containing 100 mM NaCl, 15 mM imidazole and 1 mM DTT (buffer B) with 5 M urea. Elution was carried out with a 75 ml linear gradient of 15 to 500 mM imidazole in buffer B with 5 M urea. Fractions were analyzed with SDS-PAGE and those containing the chimera were combined and concentrated to \~8 ml. The protein was then refolded at 4°C by mixing it with buffer B at a ratio of 1.5:98.5, respectively, during loading on a HisTrap 5 ml column. After loading, the column was washed with 25 ml buffer B and the protein was eluted with a 75 ml linear gradient from 15 to 500 mM imidazole in buffer B. Fractions containing the pure chimera were identified by SDS-PAGE and pooled and the buffer was then exchanged to 20 mM Hepes (pH 8.0) containing 100 mM KCl, 50 mM MgCl~2~, 50 mM Na~2~SO~4~, 10 mM NaF, 1 mM BeSO~4~ and 1 mM DTT (working buffer) using a PD 10 desalting column at 4°C. The concentration was determined from the absorption at 280 nm using an extinction coefficient of 50435 M^−1^ cm^−1^ and the protein was aliquoted and stored at −80°C for further use.

Expression and purification of DHFR~Mp~ {#s4-3}
---------------------------------------

Expression and purification of DHFR~Mp~ were achieved as before ([@bib30]) with the following changes. *E. coli* Rosetta cells harboring the Pet21d plasmid containing the DHFR~Mp~ gene were inoculated into 7 L 2 x TY medium and grown at 37°C until an O.D. of 1 was reached. IPTG (0.5 mM) was then added to induce protein expression and the cells were grown at 37°C for another 5 hr. Harvesting was carried out by spinning the cells at 11,970 g for 20 min at room temperature and then resuspending them in 100 ml buffer B containing 10 µg/ml aprotinin, 5 µg/ml antipain, 5 µg/ml pepstatin, 5 µg/ml chymostatin, 10 µg/ml leupeptin, 50 μl EDTA-free protease inhibitor cocktail (Calbiochem), 1.5 μM PMSF, 6 μg/ml RNase A, 30 µg/ml DNase and 0.22 mg/ml folate. The cells were lysed by sonication (4 cycles of 20 s sonication at 70% intensity and 60 s intervals) and one passage through a French press at 1500 atm. The lysate was centrifuged at 4°C for 30 min at 24,610 g and then for 30 min at 38,720 g. The supernatant was applied to a 5 ml His-Trap column, which was then washed with 25 ml buffer B, 25 ml buffer B containing 1 mM ATP and 50 mM MgCl~2~ and then with 25 ml buffer B again. DHFR~Mp~ was eluted with a 50 ml linear gradient of 15 mM to 500 mM imidazole in buffer B. Fractions were analyzed with SDS-PAGE and those containing DHFR~Mp~ were combined, concentrated and the buffer was exchanged to 50 mM Tris-HCl (pH 8.0) containing 250 mM NaCl, 5 mM EDTA, 5 mM β-mercaptoethanol (buffer C) using a PD-10 desalting column at 4°C. The protein was applied to a 5 ml methotrexate column, which was then washed with 20 ml buffer C. DHFR~Mp~ was eluted with a linear gradient of 70 ml from 0 to 1 mM folate and 0.25 to 1 M NaCl in buffer C. Fractions were analyzed with SDS-PAGE and those containing DHFR~Mp~ were combined, concentrated, mixed with 1 mM ATP and 50 mM MgCl~2~ and then applied to a Superdex 75 10/300 gel-filtration column equilibrated with working buffer. Fractions were analyzed by SDS-PAGE and those containing pure DHFR~Mp~ were combined, aliquoted and stored at −80°C. The protein concentration was determined using the Bradford assay and a BSA-based calibration curve.

Measurements of melting temperatures of eGFP and DHFR~Mp~ {#s4-4}
---------------------------------------------------------

The melting temperatures of eGFP and DHFR~Mp~ alone and in the chimera were measured by differential scanning fluorimetry using a StepOne real-time PCR instrument (Applied Biosystems). The protein (5 µM) alone or in the presence of 500 µM NADPH or dihydrofolate was mixed with 1X SYPRO Orange reagent (Sigma) in a 20 µl reaction volume of working buffer. The sample was heated from 4°C to 94°C with a temperature increment of 0.5°C every 45 s. The fluorescence of SYPRO Orange was measured after each temperature increment by exciting at 492 nm and measuring the emission at 610 nm. Analysis of the data was carried out using the StepOne software V2.3.

Stability measurements of the DHFR~Mp~ part of the chimera in bulk solution {#s4-5}
---------------------------------------------------------------------------

The stability of the DHFR~Mp~ part of the chimera was determined by measuring the fluorescence emission at 330 nm upon excitation at 280 nm (using an ISS PC1 fluorimeter with excitation and emission bandwidths of 16 nm) as a function of GuHCl concentration at different fixed concentrations of NADPH. Measurements were made at 23°C for samples containing about 1.4 μM of the chimera in working buffer after incubation for 10 min at the same temperature. The concentration of the stock solution of GuHCl was determined by measuring the refraction index at 23°C. The data were fitted using the following equation:$$F = \frac{F_{U}^{0} + a\left\lbrack D \right\rbrack + \left( {F_{N}^{0} + b\left\lbrack D \right\rbrack} \right)e^{\frac{- \Delta G^{0} + m{\lbrack D\rbrack}}{RT}}}{1 + e^{\frac{- \Delta G^{0} + m{\lbrack D\rbrack}}{RT}}}$$where ΔG^0^ is the free energy of unfolding in the absence of denaturant, \[D\] is the GuHCl concentration, m is the GuHCl-concentration dependence of the free energy of unfolding ($m = \frac{\partial\Delta G}{\partial\left\lbrack D \right\rbrack}$), T is the temperature and R is the gas constant. The fluorescence of the native (N) and denatured (U) states are expressed as linear functions of the GuHCl concentration with slopes of a and b, respectively. This analysis is based on the assumption that the melting curves reflect the denaturation of only the DHFR~Mp~ part of the chimera, which is justified since eGFP is very stable under our conditions and the fluorescence of its single tryptophan residue changes very little (and in a linear fashion) as a function of GuHCl concentration. The values of ΔG^0^ obtained from the fits to [Equation 3](#equ3){ref-type="disp-formula"} were then plotted as a function of the concentration of NADPH and the data were fitted using the following equation:$$\Delta G = \Delta G^{0} - RTln\left( {1 + \left\lbrack S \right\rbrack/K_{m}} \right)$$where \[S\] is the concentration of NADPH and *K*~m~ is its Michaelis-Menten constant of 13 µM ([@bib5]). Here, ΔG^0^ is the free energy of unfolding in the absence of both GuHCl and NADPH.

Encapsulation of protein substrates in GroE footballs {#s4-6}
-----------------------------------------------------

Encapsulation of eGFP and the chimera in the GroEL-GroES~2~ football was performed using different methods of denaturation. In the case of eGFP, the substrate (7.5 nmol) was denatured in 200 µl of 60 mM HCl in a siliconized test-tube. The denatured eGFP was then added slowly to 20 ml of 50 mM Tris-HCl buffer (pH 7.5) containing 100 mM KCl, 50 mM MgCl~2~, 1 mM DTT, 0.05 µM GroEL oligomer and 0.125 µM GroES oligomer (folding buffer) and left for 40 min at room temperature with mild stirring. Football assembly was initiated by adding 2 ml containing 550 mM Na~2~SO~4~, 110 mM NaF, 11 mM BeSO~4~ and 11 mM ATP (activation mix) to the folding buffer. The mixture was then stirred for 15 min at room temperature, concentrated and fractionated using a Sepharose 6 (10/300) gel-filtration column in working buffer. Fractions were analyzed by SDS-PAGE and those containing GroE-encapsulated eGFP were kept for further work. In the case of the chimera, a binary complex was first formed by incubating 9 nmol of the native chimera with \~5 nmol of GroEL oligomer in 300 µl of working buffer overnight at room temperature. The mixture was then added to a 200 µl solution containing 135 mM Na~2~SO~4~, 25 mM NaF, 2.5 mM BeSO~4~, 2.5 mM ATP and \~10 nmol of GroES oligomer, stirred for 15 min at room temperature and applied to a Superose 6 10/300 gel-filtration column.

DHFR activity assays {#s4-7}
--------------------

Activity assays were performed at 23°C in working buffer using an Infinite M200pro (TECA Group Ltd.) plate reader. Reactions were initiated by mixing 190 µl of the protein with 10 µl of NADPH (350 µM final concentration) and different concentrations of DHF. The reaction progress was followed by measuring the decrease in absorption at 340 nm as a function of time. The chimera concentrations were verified from measurements of the fluorescence emission at 509 nm upon excitation at 488 nm (with bandwidths of 4, 8 or 16 nm depending on the protein concentration) and using an eGFP-based calibration curve. Analysis and fitting of the data were performed using MatLab 2015b software.

Time-resolved fluorescence anisotropy measurements {#s4-8}
--------------------------------------------------

Fluorescence anisotropy decay curves of the target proteins were measured using a MicroTime200 fluorescence microscope (PicoQuant). Samples of eGFP and the chimera were diluted to 50--100 nM in the working buffer containing 0.01% TWEEN 20 and then loaded into a flow cell pre-coated with a lipid bilayer ([@bib13]). Molecules were excited with a 485 nm diode laser pulsed at a repetition rate of 20 MHz and with a power of 10 µW. Emitted photons were divided based on their polarization using a polarizing beam splitter cube, followed by filtration using band-pass filters (520/35 nm, BrightLine). Photon arrival times relative to the excitation pulse were registered with a resolution of 16 ps using two single-photon avalanche photo-diodes detectors (Excelitas SPCM-AQR-14-TR) coupled to a time-correlated single-photon counting module (HydraHarp 400, PicoQuant). The parallel and perpendicular fluorescence decays were constructed from the data and background corrected. Fluorescence anisotropy decays were then calculated using the following relation: $r\left( t \right) = \frac{I_{\parallel (t)} - {GI}_{\bot(t)}}{I_{\parallel (t)} + 2{GI}_{\bot(t)}}$, where $I_{\parallel (t)}$ and $I_{\bot(t)}$ are the time-dependent fluorescence intensities of the parallel and perpendicular components, and G is the polarization sensitivity factor (whose value was determined to be 1). Fluorescence anisotropy decays were fitted to a single exponential function to obtain the rotational correlation times of the proteins.
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We consider the following three-state reversible reaction:$$A\begin{matrix}
k_{1} \\
\rightleftarrows \\
k_{- 1} \\
\end{matrix}B\begin{matrix}
k_{2} \\
\rightleftarrows \\
k_{- 2} \\
\end{matrix}C$$

The rates of changes in the concentrations of A, B and C are given by:$$d\lbrack A\rbrack/dt = - k_{1}\lbrack A\rbrack + k_{- 1}\lbrack B\rbrack$$$$d\lbrack B\rbrack/dt = k_{1}\lbrack A\rbrack(k_{- 1} + k_{2})\lbrack B\rbrack + k_{- 2}\lbrack C\rbrack$$$$d\lbrack C\rbrack/dt = k_{2}\lbrack B\rbrack - k_{- 2}\lbrack C\rbrack$$

Setting d\[A\]/dt = -λ\[A\], d\[B\]/dt = -λ\[B\] and d\[C\]/dt = -λ\[C\] (where λ \>0), we can express the above three rate equations in the following matrix form:$$\begin{bmatrix}
{k_{1} - \lambda} & {- k_{- 1}} & 0 \\
{- k_{1}} & {k_{- 1} + k_{2} - \lambda} & {- k_{- 2}} \\
0 & {- K_{2}} & {k_{- 2} - \lambda} \\
\end{bmatrix}\begin{bmatrix}
{\lbrack A\rbrack} \\
{\lbrack B\rbrack} \\
{\lbrack C\rbrack} \\
\end{bmatrix} = 0$$

Given that the determinant of the above matrix must be equal to zero, one obtains:$$\lambda^{2} - \lambda\left( {k_{1} + k_{- 1} + k_{2} + k_{- 2}} \right) + \left( {k_{1}k_{2} + k_{1}k_{- 2} + k_{- 1}k_{- 2}} \right) = 0$$

[Equation A6](#equ10){ref-type="disp-formula"} has two solutions, λ~1~ and λ~2~, given by:$$\lambda_{1} + \lambda_{2} = k_{1} + k_{- 1} + k_{2} + k_{- 2}$$$$\lambda_{1}\lambda_{2} = k_{1}k_{2} + k_{1}k_{- 2} + k_{- 1}k_{- 2}$$

We can now consider two special cases described by Scheme A1, induced fit and conformational selection, both of which involve ligand binding and a conformational change. In the case of induced fit, ligand binding precedes and induces the conformational change. In the case of conformational selection, the ligand binds to one of several pre-existing conformational states and the conformational change, therefore, precedes ligand binding. In accordance with Scheme A1, the induced fit and conformational selection models can be described, respectively, as follows:$$E + S\begin{matrix}
k_{1} \\
\rightleftarrows \\
k_{- 1} \\
\end{matrix}ES\begin{matrix}
k_{2} \\
\rightleftarrows \\
k_{- 2} \\
\end{matrix}E'S$$$$E\begin{matrix}
k_{1} \\
\rightleftarrows \\
k_{- 1} \\
\end{matrix}E^{'} + S\begin{matrix}
k_{2} \\
\rightleftarrows \\
k_{- 2} \\
\end{matrix}E'S$$where E stands for the protein (enzyme), S for the substrate (ligand) and prime designates the conformational change. Assuming that ligand binding is much faster than the conformational change, one can rewrite [Equation A7](#equ11){ref-type="disp-formula"} for induced fit, as follows:$$\lambda_{1} = k_{1}\left\lbrack S \right\rbrack + k_{- 1}$$

It follows by combining [Equations A8 and A11](#equ12 equ15){ref-type="disp-formula"} that the observed rate constant is given by:$$\lambda_{2} = \frac{k_{1}k_{2}\left\lbrack S \right\rbrack}{k_{1}\left\lbrack S \right\rbrack + k_{- 1}} + k_{- 2}$$

In the case of conformational selection, one can rewrite [Equation A7](#equ11){ref-type="disp-formula"}, as follows:$$\lambda_{2} = k_{2}\left\lbrack S \right\rbrack + k_{- 2}$$

The observed rate constant in the case of conformational selection is, therefore, given by:$$\lambda_{2} = \frac{k_{- 1}k_{- 2}}{k_{2}\left\lbrack S \right\rbrack + k_{- 2}} + k_{1}$$

[Equation A14](#equ18){ref-type="disp-formula"} corresponds to [Equation 2](#equ2){ref-type="disp-formula"} in the main text. Inspection of [Equations A12 and A14](#equ16 equ18){ref-type="disp-formula"} shows that, in the case of induced fit, the value of the observed rate constant increases with increasing substrate concentration whereas, in the case of conformational selection, it decreases. The decrease, in the case of conformational selection, is due to the fact that the reaction is essentially irreversible at high \[S\] and λ~2~, therefore, tends towards *k*~1~ whereas at low \[S\] the reverse rate becomes more significant and λ~2~ tends towards *k*~1~ + *k*~-1~. In other words, the contribution of the reverse rate, *k*~-1~, is weighted by the relative reverse and forward fluxes of the second step (*k*~-2~/(*k*~2~\[S\]+*k*~-2~).

In this work, E and E' correspond to the unfolded and folded states of the protein. In the case of conformational selection, the formation of E'S (i.e. the complex of the folded protein with substrate) is governed by the rate constant λ~2~ ([Equation A14](#equ18){ref-type="disp-formula"}). The concentration of E'S is therefore given by:$$\left\lbrack {E^{\prime}S} \right\rbrack = \left\lbrack {E^{\prime}S} \right\rbrack_{ss}\left( {1 - exp^{- \lambda_{2}t}} \right)$$where \[E'S\]~ss~ is the steady-state concentration of E'S (i.e. under conditions where the substrate concentration does not become limiting) and assuming that *k*~cat~ can be neglected here. Product (P) formation is, therefore, given by:$$\frac{d\left\lbrack P \right\rbrack}{dt} = k_{cat}\left\lbrack {E^{\prime}S} \right\rbrack = k_{cat}\left\lbrack {E^{\prime}S} \right\rbrack_{ss}\left( {1 - exp^{- \lambda_{2}t}} \right)$$

Integration of [Equation A16](#equ20){ref-type="disp-formula"} yields:$$\left\lbrack P \right\rbrack = k_{cat}\left\lbrack {E^{\prime}S} \right\rbrack_{ss}t + \frac{k_{cat}\left\lbrack {E^{\prime}S} \right\rbrack_{ss}}{\lambda_{2}}\left( {exp^{- \lambda_{2}t} - 1} \right) = Vt + A\left( {exp^{- \lambda_{2}t} - 1} \right)$$where *k*~cat~\[E'S\]~ss~ corresponds to the steady-state enzyme velocity, V, and A is a constant equal to $\frac{k_{cat}\left\lbrack {E^{\prime}S} \right\rbrack_{ss}}{\lambda_{2}}$. [Equation A17](#equ21){ref-type="disp-formula"} corresponds to [Equation 1](#equ1){ref-type="disp-formula"} in the main text, which was used to fit the data of product formation vs. time as in [Figure 3](#fig3){ref-type="fig"}.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for submitting your article \"Measuring protein stability in the GroEL chaperonin cage reveals massive destabilization\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by David Ron as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as *eLife* papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.

Summary:

There is enthusiasm for the innovative approach to learn how the interior of the GroEL chaperonin chamber influences protein stability. The reviewers felt that this study potentially addresses a number of important questions about substrate confinement and GroEL mechanism. However, the implications of the work were not clearly articulated and consequently the impact of your study to the readership may not be as significant as it could be. Moreover, all reviewers felt that significantly more detail is required for a careful evaluation of the manuscript. Although no new experiments are required, a thoughtful major revision would be necessary where additional details are included. In a suitably revised version it is requested that the following points be considered:

Essential revisions:

1\) Can the authors provide more evidence that the substrate is unfolded inside the cavity prior to addition of DHF/NADPH. I presume that the temperature used is close to the melting temperature of the substrate (but I could not find it listed -- please put this in the text), but the melting temp of the substrate is measured outside of the cage so it is difficult to make the argument about what is happening inside the cavity based simply on temperatures.

2\) A related question to 1. How can the authors be certain that the transition E to E\' is actually U to N? Could this not be some binding incompetent state to one that is competent, but not necessarily U to N? And if this is the case then are the authors measuring folding/unfolding from k~1~ and k~-1~?

3\) Could the authors please provide chi-sq surfaces of k~1~ and k~-1~, as the data from which they are extracted are quite noisy.

4\) While I could derive the equations for induced fit and conformational exchange (although the authors may wish to see if there is a sign error in the eigenvalues -- negative of what they are listed), I could not understand Equation 1. Please derive this equation as well, as it is critical to understanding the paper, making the link between the derivation that the authors have given for the lamda in appendix and how this explicitly relates to product formation as per Equation 1.

5\) A major concern is that the authors use a species of GroEL/ES that is favored by beryllium fluoride with two GroES rings bound to the GroEL tetradecamer. This state is meant to mimic a state after a substrate is released into the cavity and in general would be assumed to be favored to fold. However, the relevance of the state the authors have used, apparently because it is stable and does not allow leakage of the trapped protein, to the mechanism of GroEL/ES is not argued convincingly. So the goal of the study is not clear: is it to show that entrapment in a small cavity can have destabilizing effects on a protein? or is it to contribute to understanding of the GroEL mechanism?

6\) It was shown that eGFP doesn\'t leak from the GroEL/ES bullet, but not the chimera. Why was this not tested?

7\) The paper is very brief and lacks a clear conclusion about the significance of the observations. The authors refer to the iterative annealing mechanism without any description or explanation of how their result relates.

8\) It was unclear what the authors did differently that enabled them to confine the chimera in the cavity where previous attempts failed. Perhaps, the authors can spell this out.

9\) The attachment of eGFP does destabilize DHFR a lot and eGFP as well. One assumes that the results in Figure 2 and subsection "Design and construction of a model protein substrate" are in bulk, although this was not spelt out explicitly. Please confirm.

10\) The argument, in the last paragraph of the subsection "Folding of the DHFR~Mp~ part of the chimera in the GroEL cavity", that the decay of fluorescence anisotropy of the two proteins are similar in the cavity and bulk, which is the basis for ruling out interaction with the wall being the cause of the destabilization. This is reasonable. Two naïve questions:

i\) The decay simply suggests that the overall shape is the same but cannot rule out weak interactions. The decrease in the amplitude is not very large in either situations. Does this mean a \"preferred\" orientation?

ii\) On time scales greater that about 18 ns (Figure 5) there is more dispersion (conformational variability?) in the caged construct. Is there an explanation or does this not matter?

11\) The authors conclude that the effect could be due to diminished hydrophobic effect in the confined space. The authors might want to know that this was established in MD simulations (PNAS 105: 17636 (2008)) by calculating the potential of mean force between a few amino acid side chains (polar, charged, and hydrophobic). Among these it was clear that interactions between hydrophobic residues were diminished in a cylindrical cavity, supporting the conclusion here, whereas others are more nuanced. The authors realize that the results that the magnitude of the effects could be substrate specific. But given that the hydrophobic interactions might be the determining factor (assuming it holds) do they the authors think that the results are very general. In other words, destabilization should be the norm, which is in accord with the expectation of the iterative annealing mechanism.
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Author response

> Essential revisions:
>
> 1\) Can the authors provide more evidence that the substrate is unfolded inside the cavity prior to addition of DHF/NADPH. I presume that the temperature used is close to the melting temperature of the substrate (but I could not find it listed -- please put this in the text), but the melting temp of the substrate is measured outside of the cage so it is difficult to make the argument about what is happening inside the cavity based simply on temperatures.

The temperature used, which is indeed close to the melting temperature in bulk solution, was stated in the Materials and methods of the original version and in the revised paper is mentioned also in the main text. Please see response below for more.

> 2\) A related question to 1. How can the authors be certain that the transition E to E\' is actually U to N? Could this not be some binding incompetent state to one that is competent, but not necessarily U to N? And if this is the case then are the authors measuring folding/unfolding from k~1~ and k~-1~?

This is an excellent point. Formally, a similar kinetic behavior would be observed for a scheme $\left. E\prime\rightleftarrows E_{F}\rightleftarrows ES \right.$, i.e. when the equilibrium is between the folded protein and a mis-folded inactive species, E'. This possibility is unlikely, however, because it was found that only 20% of human DHFR mis-folds inside the cavity of the non-cycling complex of single-ring GroEL with GroES (Horst et al., 2007). In such a case, the expected lag phase due to the mis-folded population would not be observed owing to the activity of the remaining DHFR, which does not mis-fold. Moreover, according to this model, the mis-folded state is much more stable than the folded state, which is in violation of Anfinsen's dogma that the native state is at the minimum free energy if the conditions in the cavity are assumed to favor folding. This discussion was added to the paper.

> 3\) Could the authors please provide chi-sq surfaces of k~1~ and k~-1~, as the data from which they are extracted are quite noisy.

We thank the reviewer for this suggestion. The revised version contains a reduced chi-square surface analysis, which validates our estimates of k~1~ and k~-1~. We also reanalyzed the data, which were used to extract the values of lamda, in order to ensure that the linear phase is fully included until substrate depletion sets in and that deviations from linearity owing to substrate depletion are excluded. The reanalysis led to small changes in some of the lamda values and the impact on the values of the k~1~ and k~-1~ and the free energy of folding in the cavity is also small.

> 4\) While I could derive the equations for induced fit and conformational exchange (although the authors may wish to see if there is a sign error in the eigenvalues -- negative of what they are listed), I could not understand Equation 1. Please derive this equation as well, as it is critical to understanding the paper, making the link between the derivation that the authors have given for the lamda in appendix and how this explicitly relates to product formation as per Equation 1.

The appendix now also contains the derivation of Equation 1 and the link to λ. The apparent sign error was also fixed. The confusion was due to defining -λ as λ.

> 5\) A major concern is that the authors use a species of GroEL/ES that is favored by beryllium fluoride with two GroES rings bound to the GroEL tetradecamer. This state is meant to mimic a state after a substrate is released into the cavity and in general would be assumed to be favored to fold. However, the relevance of the state the authors have used, apparently because it is stable and does not allow leakage of the trapped protein, to the mechanism of GroEL/ES is not argued convincingly. So the goal of the study is not clear: is it to show that entrapment in a small cavity can have destabilizing effects on a protein? or is it to contribute to understanding of the GroEL mechanism?

The reviewer is correct in stating that it has often been assumed that folding is favored in the cavity of GroEL bound to ATP and GroES but this has never been measured. By contrast, the effects of other states such as apo GroEL and ATP-bound GroEL are better understood. Our goal was to isolate the effect of this state from the effects of other states, which co-exist when the system is cycling. Surprisingly, we found that encapsulation in the cavity of GroEL bound to ATP and GroES can lead to massive destabilization. A new paragraph was added to the Conclusions to clarify this point and relate it to GroEL's mechanism.

> 6\) It was shown that eGFP doesn\'t leak from the GroEL/ES bullet, but not the chimera. Why was this not tested?

Given that eGFP doesn't leak it seemed unnecessary to test whether a larger protein containing eGFP leaks. Moreover, we had tested before whether two other proteins, the p53 core domain (22.4 kDa) and the chimera of EnHD with eGFP (42.9 kDa), leak and found that neither does. We've added this information to the paper.

> 7\) The paper is very brief and lacks a clear conclusion about the significance of the observations. The authors refer to the iterative annealing mechanism without any description or explanation of how their result relates.

A brief but hopefully clear description of the iterative annealing mechanism and how our result relates to it has been added to the Conclusions.

> 8\) It was unclear what the authors did differently that enabled them to confine the chimera in the cavity where previous attempts failed. Perhaps, the authors can spell this out.

In the subsection "Identifying conditions for minimizing escape of encapsulated substrates", we now state explicitly that we did not encapsulate the substrate in the cavity formed by single-ring GroEL with GroES, which was believed to be non-leaky.

> 9\) The attachment of eGFP does destabilize DHFR a lot and eGFP as well. One assumes that the results in Figure 2 and subsection "Design and construction of a model protein substrate" are in bulk, although this was not spelt out explicitly. Please confirm.

These results are indeed for bulk solution as stated explicitly in the text and legend to Figure 2 of the revised version,

> 10\) The argument, in the last paragraph of the subsection "Folding of the DHFR~Mp~ part of the chimera in the GroEL cavity", that the decay of fluorescence anisotropy of the two proteins are similar in the cavity and bulk, which is the basis for ruling out interaction with the wall being the cause of the destabilization. This is reasonable. Two naïve questions:
>
> i\) The decay simply suggests that the overall shape is the same but cannot rule out weak interactions. The decrease in the amplitude is not very large in either situations. Does this mean a \"preferred\" orientation?

We think that weak interactions would decrease rotational diffusion and therefore lead to longer anisotropy decay time. Therefore the similarity of the decays suggests that such interactions are not significant.

> ii\) On time scales greater that about 18 ns (Figure 5) there is more dispersion (conformational variability?) in the caged construct. Is there an explanation or does this not matter?

The 'dispersion' is not conformational variability but noise. This noise occurs because the fluorophore has to a large extent decayed already, so the polarization signal is a difference between two very small signals divided by a sum of two small signals, which means a lot of noise. This has nothing to do with the conformational dynamics, though, and in fact the noise in the green and red signals looks similar.

> 11\) The authors conclude that the effect could be due to diminished hydrophobic effect in the confined space. The authors might want to know that this was established in MD simulations (PNAS 105: 17636 (2008)) by calculating the potential of mean force between a few amino acid side chains (polar, charged, and hydrophobic). Among these it was clear that interactions between hydrophobic residues were diminished in a cylindrical cavity, supporting the conclusion here, whereas others are more nuanced. The authors realize that the results that the magnitude of the effects could be substrate specific. But given that the hydrophobic interactions might be the determining factor (assuming it holds) do they the authors think that the results are very general. In other words, destabilization should be the norm, which is in accord with the expectation of the iterative annealing mechanism.

A discussion of this issue and its relevance to our work was added to the Conclusions. We thank the reviewer for pointing out this reference, which we cite in the revised paper.
